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ABSTRACT
Leptin (OB protein) is an important signal in the regulation of
energy balance. Leptin levels correlate with adiposity, but also de-
crease acutely with caloric restriction and increase with refeeding.
The brain is an established critical site of leptin function, yet little is
known about leptin concentrations in the central nervous system
relative to plasma levels, psychiatric diagnoses, and other endocrine
parameters. Therefore, using a novel ultrasensitive leptin assay, we
explored relationships of human plasma and cerebrospinal fluid
(CSF) leptin levels to body mass index, smoking, posttraumatic stress
disorder diagnosis, and levels of dopamine, monoamine metabolites,
b-lipotropin, glucocorticoid, and thyroid and cytokine hormones. A
strong linear relation between CSF and plasma leptin levels in the am
(r 5 0.63; P , 0.002) and afternoon (r 5 0.90; P , 0.0001) was
revealed. CSF and plasma leptin concentrations decreased during a
12- to 20-h period of fasting. A strong association was found between
plasma leptin and CSF dopamine levels (r 5 0.74; P , 0.01) as well
as between CSF leptin levels and urinary free cortisol (r 5 0.73; P ,
0.01). Both of these parameters covaried with leptin independently of
adiposity, as estimated by body mass index. Implications for leptin
transport, regulation, and its potential role in therapeutic strategies
for obesity and diabetes are discussed. (J Clin Endocrinol Metab 84:
3579–3585, 1999)
THE ADIPOCYTE-SECRETED hormone leptin is impli-cated in the regulation of energy homeostasis as a pro-
tein that signals the central nervous system (CNS) to decrease
food intake and adiposity (1). Leptin is secreted in proportion
to the amount of adipose tissue (2, 3) and exhibits a diurnal
pattern of peak concentrations at night that are related to
insulin responses to meals (4, 5). Accordingly, leptin con-
centrations have been shown to decrease in response to fast-
ing or energy restriction and increase after refeeding (6–8).
Decreases in circulating leptin are related to increased sen-
sations of hunger during energy restriction in humans (9).
Rodents (10–12) and humans (13, 14) with homozygous mu-
tations in the leptin or leptin receptor genes manifest hy-
perphagia and obesity. In rodents, central administration of
leptin decreases food intake and body weight (15–17) and
increases energy expenditure (18). Central infusion of leptin
also decreases food intake while activating the sympathetic
nervous system in nonhuman primates (19). Activation of
leptin receptors throughout the hypothalamus is believed to
be critical for these anorectic effects (20–22).
In humans, cerebrospinal fluid (CSF) and circulating pe-
ripheral levels of leptin are positively correlated (1, 23, 24).
However, in individuals with high levels of circulating leptin
(and high levels of body fat), the CSF to plasma concentration
ratio is lower than that in nonobese individuals (1, 24). This
finding subsequently led to investigations into the transport
mechanisms of leptin uptake, mechanisms that may be com-
promised in obesity. These are hypothesized to include sat-
urable receptor binding at the blood-brain barrier (1, 25),
decreased transport via receptor binding at the choroid
plexus (26), or nonsaturable diffusion (24).
Despite evidence that the brain is a critical site of leptin
action, a paucity of data exist on human CSF leptin, partic-
ularly in terms of its relationship with other neural and
endocrine variables and how they may correlate over time.
One exception is a study that assessed relationships between
CSF and serum leptin levels and CSF and serum levels of
neuropeptide Y. Covariability between leptin and neuropep-
tide Y was not found (23).
Although single datum point CSF samples of leptin have
helped shed light on the nature of this hormone’s transport
into the CNS (1, 24), serial sampling of CSF in humans via a
flexible, indwelling catheter may have significant advan-
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tages over one-time CSF sampling (27–29). We now extend
the use of this repeated CSF-sampling technique to explore
covariability of CSF leptin concentrations, not only with
plasma leptin levels, but with other bioactive substances not
previously examined in relationship to CSF leptin.
Specifically, morning (am) and evening (pm) CSF and
blood samples were collected from male participants and
variously assayed for leptin, dopamine, dopamine and se-
rotonin metabolites, CRH, interleukin-6 (IL-6), immunore-
active b-lipotropin (irb-lipotropin), and thyroid hormones.
Urinary free cortisol (UFC) excretion was measured over a
24-h period. In addition to these neuroendocrine variables,
covariabilities between these substances and leptin levels
were examined as a function of diurnal phase, body mass
index (BMI), tobacco smoking, and medical diagnosis of
posttraumatic stress disorder (PTSD).
Materials and Methods
Participants
Approval for the study was obtained from the institutional review
board of the University of Cincinnati Medical Center and the Veterans
Affairs Medical Center (Cincinnati, OH). Informed consent from each
patient or volunteer was obtained before their participation. The par-
ticipants were all men between 23–50 yr of age. Ten were combat vet-
erans meeting the DSM-IV criteria (30) for PTSD but with no other
medical problems. Seven of these patients had been taking prescribed
antidepressants, but abstained from them for at least 2 weeks or five
disappearance half-lives before the study. Ten additional volunteers
were age-matched healthy men with no history of substance abuse or
other psychiatric illness and no first degree relatives with these condi-
tions. Before the study each participant underwent standard physical,
blood, and urine tests to rule out abnormalities.
CSF, plasma, and urine collection
On the evening before the study, participants ate a standard 666-cal
meal (20% protein, 24% fat, and 56% carbohydrate) and fasted for ap-
proximately 12 h before insertion of a 20-g Teflon indwelling lumbar
catheter as previously described (28) except that subjects were placed in
the seated position. The catheter was advanced 5–15 cm cephalad into
the subarachnoid space and was secured from 0800–1700 h while CSF
was collected into iced test tubes at a rate of 0.1 mL/min from a Tygon
tube extension attached to a peristaltic pump. Physiological saline so-
lution was infused at 100 mL/h throughout the procedure through an
antecubital vein. Blood was withdrawn every half-hour from an in-
dwelling venous catheter, and all urine was collected. No smoking or
oral intake was permitted during the study. Participants were confined
to bed rest beginning the midnight before CSF sampling.
Sensitive human leptin assay
A new RIA was developed to sensitively measure low levels of
human leptin in CSF, serum, plasma, or culture medium samples (Linco
Research, Inc., St. Charles, MO). The assay used a polyclonal antibody
raised in rabbits against highly purified recombinant human leptin.
Calibrators (0.05, 0.1, 0.2, 0.5, 1.0, 2.0, 5.0, and 10.0 ng/mL) and 125I-
labeled tracer were prepared with recombinant human leptin. Calibra-
tors (100 mL) or CSF and plasma specimens (25–100 mL) in duplicate
were mixed with antibody (100 mL) and incubated overnight (20–24 h)
at room temperature. If the specimen volume was less than 100 mL, the
remaining volume was adjusted with assay buffer. [125I]Leptin (100 mL)
was added, and the samples were mixed and then incubated for an
additional 20–24 h at room temperature. One milliliter of cold (4 C)
precipitating reagent (antirabbit rabbit IgG) was added to all tubes
(except total count tubes) to precipitate the antibody-antigen complex.
Tubes were centrifuged at 4 C for 20 min at 2500 3 g. The supernatants
were decanted, and the pellets were counted to determine bound ra-
dioactivity. Calculation of unknown leptin concentrations in samples
was performed by log-logit transformation. Coefficients of variation at
leptin concentrations between 0.44–4.24 ng/mL ranged from
3.74–7.28% within runs and from 3.24–8.90% between runs.
Recovery of different amounts (range, 0.2–2.0 ng/mL) of recombinant
human leptin to added human serum averaged 104–118%. Linear di-
lution of four pooled human serum samples with concentrations ranging
from approximately 1.1–4.2 ng/mL was assessed by measuring each
five times at volumes of 100, 75, 50, and 25 mL after dilution with assay
buffer. Values of 97 6 2%, 93 6 5%, and 81 6 6% of the measured
concentrations at 100 mL were measured at 75, 50, and 25 ml, respectively.
Concentrations of leptin in human serum measured with the new sen-
sitive RIA (catalogue no. SHL-81K) were very similar, with a slope close
to 1.0 (y 5 1.04x 1 0.68), and were highly correlated (r 5 0.985) with
concentrations determined with the standard human leptin RIA (cata-
logue no. HL-81K) (31).
Monoamine and hormone assays
CSF samples were also assayed for dopamine (picomoles per mL), the
dopamine metabolite homovanillic acid (HVA; picomoles per mL), the
serotonin metabolite 5-hydroxyindoleacetic acid (5HIAA; picomoles per
mL), the cytokine IL-6 (picograms per mL), CRH (picograms per mL),
and irb-lipotropin (picograms per mL). Plasma samples were also as-
sayed for 5HIAA, TSH (microinternational units per mL), total T3 (TT3;
nanograms per dL), T4 (nanograms per dL), HVA, and IL-6. Urine
samples were collected for analysis of UFC (micrograms per 24 h).
Dopamine, HVA, and 5HIAA were assayed via HPLC with an elec-
trochemical detection as described previously (29). IL-6 was quantified
with a commercial enzyme-linked immunosorbent assay kit (Endogen,
Inc., Woburn, MA), using sets of paired monoclonal antibodies for
capture and detection. The mean inter- and intraassay coefficients of
variation for the control phase were less than 10%, and the detection limit
was less than 1 pg/mL. RIAs, with the modifications described previ-
ously, were used to quantify CRH (28) and irb-lipotropin (27). TSH, TT3,
and T4 in blood and UFC were assayed by standard thyroid and free
cortisol profiles at the Veterans Affairs Clinical Laboratory in Cincinnati.
Statistical analysis
ANOVA was used to assess differences between leptin levels and
dichotomous variables, including clinical diagnosis and cigarette smok-
ing. Paired t tests were used to assess differences between am and pm
leptin levels within participants. Leptin values were regressed on be-
havioral and neuroendocrine variables. Partial correlation coefficients
were obtained on variables found to be associated with leptin levels to
control for potential confounds. When not normally distributed, data
were logarithmically transformed for the best description of relation-
ships and omitted if outside of 3 sd. BMI was calculated as weight in
kilograms divided by height in meters squared. Data represent the
mean 6 sem. Except for CRH and IL-6, for which one am and one pm
sample each were analyzed, values entered into the analyses for all other
biological variables represent the mean concentrations of samples col-
lected at regular intervals from 1100–1700 h. Significance levels for
two-tailed tests (except for one-tailed where noted) were set at P , 0.05.
Results
Relationship among leptin levels, medical diagnosis, and
cigarette smoking
No significant differences were found in CSF and plasma
leptin concentrations between the PTSD and normal volun-
teer groups. Therefore, data from all participants were
treated collectively in the analysis of leptin results. Cigarette
smokers and nonsmokers could not be differentiated on the
basis of CSF or plasma leptin levels, but were better predicted
by a decrease in the CSF concentration of HVA and an in-
crease in the plasma concentration of 5HIAA (r 5 20.696; P ,
0.001 and r 5 0.487; P , 0.035, respectively), as previously
reported (32).
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Relationship between leptin levels and BMI
The mean BMI of the participants was 27.0 6 1.0 kg/m2
(range, 18.9–35.8). BMI was positively associated with am
CSF (r 5 0.42; P , 0.03), pm CSF (r 5 0.62; P , 0.01), am
plasma (r 5 0.62; P , 0.01), and pm plasma leptin levels (r 5
0.68; P , 0.01). Thus, 18–46% of the variance in leptin levels
could be explained by differences in BMI.
Relationships between CSF and plasma leptin levels
Mean plasma leptin concentrations were lower in the pm
(3.6 6 0.5 ng/mL) than in the am (4.6 6 0.7 ng/mL; P , 0.01),
and were strongly correlated with each other (r 5 0.90; P ,
0.001). CSF leptin levels, also, decreased significantly from
am (0.07 6 0.02 ng/mL) to pm (0.047 6 0.01 ng/mL; P , 0.05)
and were strongly correlated with each other (r 5 0.85; P ,
0.001). As depicted in Fig. 1A, am CSF and plasma leptin
concentrations were positively related (r 5 0.63; P , 0.002).
Figure 1B shows that this relationship was stronger toward
late afternoon (r 5 0.88; P , 0.001). In addition and as shown
in Fig. 1C, am plasma levels of leptin were highly predictive
of afternoon leptin levels in the CSF (r 5 0.85; P , 0.001).
Analysis of CSF/plasma leptin ratios
The CSF/plasma ratio was used as an indicator of the
efficiency of adipose-secreted leptin transport into the brain.
As shown in Fig. 2A there was a positive correlation between
the CSF/plasma ratio and plasma leptin levels (r 5 0.51; P ,
0.01) in the am. As depicted in Fig. 2B, after additional time
without food (pm samples) the positive correlation between
CSF/plasma ratio and plasma leptin levels was stronger (r 5
0.56; P , 0.005). As expected, BMI, which was strongly cor-
related with plasma leptin levels, was found to similarly
correlate with the CSF/plasma ratio.
Relationship between leptin and neuroendocrine variables
As shown in Table 1, simple regression coefficients for
leptin levels regressed on various neuroendocrine variables
yielded significant associations with dopamine, UFC, TT3,
and irb-lipotropin. Because BMI was significantly interre-
lated with several of the biological variables, partial corre-
lations controlling for BMI were obtained from these signif-
icant leptin-neuroendocrine relationships.
The effect of partialing out variance due to BMI is shown
in Table 2. As a result of these analyses, levels of plasma TT3
and CSF irb-lipotropin were found to covary mostly as a
function of BMI and not leptin. CSF dopamine levels were
found to covary with plasma leptin levels. Twenty-four-hour
UFC excretion was significantly associated with CSF leptin
and marginally with am plasma leptin concentrations. Both
of these relationships were significant after controlling for
BMI.
Discussion
This study examined concentrations of leptin in plasma
and CSF across time and with levels of other plasma- and
brain-derived neuroendocrine substances in humans. CSF
and blood samples were taken from volunteers who had
fasted for 12 h when the first samples were taken and for an
additional 8 h when the last samples were obtained. We were
able, therefore, to explore covariability in the concentrations
of these neuroendocrine substances against a background of
increasing duration of fasting in individuals with a range of
body fat mass.
Our results confirm the existence of a strong linear rela-
tionship between CSF and plasma leptin levels as has been
reported in previous studies (23, 24). Additionally, we found
this relationship to grow stronger toward evening, as par-
ticipants approached 20 h of fasting and when mean con-
FIG. 1. A, Relationship between the mean am leptin level in plasma
and CSF of all participants (n 5 20). B, Relationship between the
mean pm leptin level in plasma and CSF of all participants (n 5 20).
C, Relationship between the mean am leptin level in blood and the pm
leptin level in CSF of all participants (n 5 20). Strikes through open
circles represent overlapping data from more than one participant.
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centrations of both plasma and CSF leptin decreased. This
observed pattern is also consistent with prior reports of de-
creases in plasma leptin concentrations with caloric restric-
tion (6–9), and extends them by showing that CNS leptin
levels also decrease under these conditions. Decreased adi-
pocyte glucose metabolism resulting from a lowering of cir-
culating insulin levels during the caloric deficit would result
in a decrease in leptin production (33). Decreased leptin
levels in CNS are likely to be a direct result of attenuated
leptin transport into the CNS due to lower plasma leptin
levels.
CSF/plasma leptin ratios were examined as a function of
the amount of plasma leptin present (or BMI), and as a
function of caloric restriction. In the am, following an over-
night fast (12 h without food), high plasma leptin concen-
trations were associated with high CSF/plasma leptin ratios.
This pattern is different from that observed by Schwartz et
al. (22), Caro et al. (1), and Dotsch et al. (23), where in par-
ticipants who similarly fasted overnight, there was a nega-
tive correlation between their CSF/plasma leptin ratios and
plasma leptin. The pattern of decreased CSF/plasma con-
centrations with increasing plasma leptin concentrations
(and increasing BMI) has been interpreted in terms of a leptin
transport system that becomes saturated in the presence of
higher levels of plasma leptin (1, 24–26).
An explanation for the observed differences in the patterns
of CSF/plasma ratios may be due to differences in BMI
ranges between the studies. The mean BMIs for the three
subgroups in the study by Schwartz et al. (22) were reported
to be between 22.9–24.9 (the heaviest quantile of the entire
groups was 26.1 6 0.6). Participants in the study by Dotsch
et al. (23) were all lean and of average weight. In sharp
contrast, 78% of our group ranged in BMI from 26.2–35.8. In
the study by Caro et al. (1), the subjects included obese
participants (mean BMI, 31.7), but six of eight of the indi-
viduals were women. Serum leptin levels have been shown
to be consistently higher in women than in men (24, 34)
before and after restriction (7), whereas CSF concentrations
have been found not to differ (35). Higher plasma levels
would be expected to yield smaller CSF/plasma ratio values,
possibly shifting a positive correlation to a negative one.
Our results with an all-male group that included over-
weight and obese individuals with high BMIs do not support
the hypothesis that CSF leptin transport is attenuated with
increasing plasma leptin (and BMI). Analysis revealed
higher, not lower, CSF/plasma ratios with increasing plasma
leptin. CSF leptin transport as a function of peripheral leptin
concentrations may, therefore, be more accurately described
as an inverted U function with possibly an alternate transport
mechanism acting in response to excessive plasma leptin
such as occurs in obesity. Caro et al. (1) proposed that perhaps
very high levels of plasma leptin may be sufficient to increase
leptin transport into the CNS. They noted the unusual case
of a patient with unusually high serum leptin levels who
showed a lean pattern of correspondingly high CSF leptin
level. This case, although probably atypical, would be con-
sistent with a hypothesized U-shaped function of leptin
transport. Certainly, additional studies with individuals fall-
ing within a large range of BMIs and in which females and
males are analyzed separately would be needed to provide
support for this alternate hypothesis.
Unique to the present study is that leptin was assayed in
the same individuals a second time, after further restriction
from food intake (for a total of 20 h). At this time, the positive
association between plasma leptin levels and CSF/plasma
leptin ratios was strengthened. Plasma leptin levels declined
from the first sampling, as would be expected with further
energy restriction (6–8). Within certain limits, plasma leptin
during caloric restriction may be more efficiently transported
into brain via an unsaturated transport mechanism. Such
high CSF/plasma ratios with low plasma leptin would rep-
resent the left curve of an inverted U function. Consistent
with this idea, patients with anorexia nervosa who have low
levels of plasma leptin concurrent with their low body fat
content and restricted energy intake were found to have high
CSF/plasma leptin ratios (36).
Another goal of this study was to explore the relationship
between CSF and plasma leptin levels with psychiatric di-
agnoses (tobacco dependence and PTSD) and several neu-
roendocrine variables not previously studied in relationship
FIG. 2. A, Correlations between the mean am CSF/plasma leptin
ratio and concentration of am plasma leptin (n 5 18). B, Correlations
between the mean pm CSF/plasma ratio and concentration of pm
plasma leptin (n 5 20). Strikes through open circles represent over-
lapping data from more than one individual.
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to leptin. Cigarette smoking has previously been reported to
predict circulating leptin levels (37). However, this relation-
ship was weak (P , 0.1), and so our finding of a lack of any
predictive value of smoking use on leptin levels was not
surprising. A more reliable predictor of cigarette smoking, at
least after an overnight period of abstinence, appears to be
decreased CSF levels of the dopamine metabolite HVA (32).
A history of combat-related PTSD, although not signifi-
cantly associated with changes in leptin concentrations, was
found to be associated with elevated levels of irb-lipotropin
(27) and decreased TT3. However, irb-lipotropin and TT3
were also strongly interrelated with levels of body fat, which
were higher among the veterans in this particular sample.
BMI, in fact, was associated with many of the neuroendocrine
variables measured besides irb-lipotropin and TT3, including
plasma IL-6, UFC, and CSF 5HIAA. Similar findings in
healthy volunteers have been found between BMI and IL-6
(38) and cortisol (39). Our findings support the reliability of
such interactions and stress the importance of considering
body fat levels when interpreting the significance of hor-
mone/neurotransmitter covariability.
Of primary interest are those variables that were found to
be associated with leptin levels independently of BMI,
namely 24-h UFC excretion and dopamine. The positive re-
lationship between UFC and leptin observed here is consis-
tent with a number of other observations. In humans, oral
administration of cortisol has been shown to produce dose-
and time-dependent increases in plasma leptin levels (40),
and patients with acute sepsis and elevated plasma cortisol
concentrations also have 3-fold higher concentrations of
plasma leptin relative to healthy controls (41). These eleva-
tions, however, may have been due to administration of
steady glucose infusions that would disrupt the normal di-
urnal pattern of circulating leptin concentrations seen with
intake of regular meals (4). The mechanism for the relation-
ship between UFC and leptin, however, is also somewhat
unclear. UFC levels are a product of activity of the hypo-
thalamic CRH system as part of the classic hypothalamic-
TABLE 1. Pearson correlation coefficients for neuroendocrine variables
Variables am CSF leptin pm CSF leptin am P leptin pm P leptin
CSF-derived
Dopamine 0.250 0.433a 0.464a 0.583b
HVA 20.126 0.046 20.013 0.078
DA:HVA 0.196 0.147 0.282 0.214
5HIAA 0.166 0.319 0.297 0.316
5HIAA:HVA 0.316 0.205 0.406 0.206
irb-lipotropin 0.322 (0.428a) (0.417a) (0.417a)
IL-6 (am) 20.225 20.258 0.039 20.184
IL-6 (pm) 0.167 0.176 0.212 0.025
TSH 20.215 20.207 20.117 20.214
TT3 20.131 20.280 20.532
a 20.516a
T4 0.297 0.248 0.139 0.047
Plasma-derived
HVA 20.083 20.088 0.054 20.050
5HIAA 0.243 0.078 0.297 0.224
CRH (am) 0.020 20.062 0.203 0.153
CRH (pm) 0.028 0.060 0.054 0.035
IL-6 (am) 0.129 0.269 0.270 0.345
IL-6 (pm) 0.119 0.267 0.271 0.350
Urine
UFC 0.773b 0.768b 0.638b 0.556a
All tests of significance were two-tailed except those in parentheses, which indicate one-tailed significance.
a P , 0.05.
b P , 0.01.
TABLE 2. Simple and partial correlation coefficients between leptin and neuroendocrine variables after controlling for BMI
Dependent variable Independent variable ra pr P
CSF leptin (am) UFC 0.773 0.735 ,0.01
CSF leptin (pm) Dopamine 0.433 0.362 NS
irb-lipotropin 0.428 0.170 NS
UFC 0.768 0.661 ,0.01
Plasma leptin (am) Dopamine 0.464 0.728 ,0.01
irb-lipotropin 0.417 0.149 NS
TT3 20.532 20.032 NS
UFC 0.638 0.491 ,0.05
Plasma leptin (pm) Dopamine 0.583 0.743 ,0.01
irb-lipotropin 0.417 0.120 NS
TT3 20.516 20.084 NS
UFC 0.556 0.317 NS
pr, Partial correlations controlling for BMI.
a All correlations were significant (P , 0.05) before controlling for BMI.
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pituitary-adrenal axis. Hence one possible explanation for
the relationship between UFC and leptin would be a direct
action of leptin to increase CRH activity in the hypothalamus.
Several lines of evidence from rodent (22, 42–44) and hypo-
thalamic explant studies (45) do indeed point to leptin in-
creasing CRH activity, although some degree of controversy
regarding this topic remains (46, 47). However, the current
data show no relationship between CRH and leptin or be-
tween CRH and UFC. This suggests two possible hypotheses.
First, the relationship between leptin and UFC may not be
mediated by the CRH system, but by some other mechanism.
Alternatively, the CRH measurements in CSF reported here
are the product of predominantly extrahypothalamic sources
of CRH (48) and thereby obscure the relationship between
leptin and hypothalamic CRH as well as between UFC and
hypothalamic CRH.
Of the neurotransmitters assayed in CSF, dopamine was
strongly correlated with plasma leptin levels. Both plasma
leptin and CSF dopamine were positively correlated inde-
pendent of adiposity, as assessed be the BMI. Interestingly,
in contrast to the vast number of studies devoted to leptin-
HPA interactions, virtually none has explored the potential
interaction between leptin and dopamine. Similar to the an-
orectic effect of leptin in animals, pharmacological agents
that increase dopamine release or inhibit dopamine re-
uptake, such as cocaine and amphetamines, are well known
to potently reduce appetite in animals and humans (49, 50).
Bromocriptine, a dopamine D2 agonist, and other dopamine
agonists, including SKF38393 and BC/SKF, alone and in
combination dramatically reduce body fat, glucose, and in-
sulin levels in hamsters (51) and ob/ob mice (52). These agents
also appear to improve basal insulin release in ob/ob mice (53)
and ameliorate islet dysfunction in db/db mice (54).
In obese, nondiabetic, hyperinsulinemic women, bro-
mocriptine significantly decreases cholesterol, PRL, glucose,
and tryglyceride levels (55). Taken daily, bromocriptine pro-
duces a 25% reduction of body fat after 6 weeks in females
and reduces hyperglycemia in diabetic subjects (56). High
insulin and glucose levels are associated with increased
plasma leptin (37, 57, 58), which may also be regulated by a
dopamine system (52). Furthermore, the existence of leptin
receptors on tyrosine hydroxylase (dopamine-synthesizing)
neurons in the dorsomedial nucleus of the hypothalamus
lends neuroanatomical support for a leptin-dopamine inter-
action (59).
In summary, our data show a consistent covariation in
humans between CSF and plasma leptin concentrations that
is sustained throughout 18 h of fasting. Fasting was associ-
ated with a significant decline in CSF as well as plasma leptin
levels. The present data also reveal several relationships be-
tween leptin and other neuroendocrine parameters, such as
5HIAA, irb-lipotropin, TT3, and IL-6, that were largely de-
pendent on BMI. These observations underscore the impor-
tance of assessing the influence of BMI or adipose mass in
clinical studies of CNS neuroendocrine parameters. Of par-
ticular interest was the positive and independent relation-
ships between CSF leptin levels and 24-h UFC excretion and
between plasma leptin levels and CSF dopamine concentra-
tions. These relationships remained strong despite a decline
in leptin with continued food restriction. These findings sug-
gest additional roles for leptin in neuroendocrine regulation
that may contribute to the central regulation of food intake
and energy balance. Furthermore, this study raises the pos-
sibility that dopaminergic systems are involved in the effects
of leptin, and this interaction might be dysregulated in obe-
sity. It is therefore possible that the mechanism by which
dopamine agents ameliorate symptoms of diabetes and obe-
sity involves leptin. Prospective studies of individuals with
obesity, diabetes, and other disorders of compromised neu-
roendocrine and metabolic systems are needed to elucidate
the role of leptin interactions with glucocorticoids and do-
pamine in the etiology and maintenance of these conditions
and to help develop efficacious treatment strategies.
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